heart disease. Hearing loss. addiction. Chronic pain. Alzheimer’s disease. ALS. These are some areas Yililairinse with GLP-1 drug cash, want to bet a lot.
Dan Skovronsky, chief scientific officer of Eli Lilly, said the ideas were “hidden in sight.” They are places other pharmaceutical companies may not want to go because they are difficult to solve.
“As for the moment, we are indeed the largest healthcare company in the world, which is probably the largest healthcare company ever, and we have an obligation,” Skovlensky said. “Investors gave us a vote of trust. We think , It’s the obligation to invest in some big issues hidden in sight, trying to make a difference to your community’s health.”
Lilly’s Tirzepatide sold the company with diabetic Mounjaro and obese Zepbough. Since Mounjaro was approved in 2022, the company’s sales have increased by nearly 60%. Eli Lilly’s shares have risen 268% over the past three years, bringing the company’s market capitalization to $823. Billion dollars – the highest of any healthcare company.
Now, the company hopes to successfully translate into other disease areas.
Lilly has tested whether its drug Kisunla can prevent Alzheimer’s disease. Kisunla is a monoclonal antibody that removes brain amyloid plaques associated with memory diseases. Currently, it has approved the treatment of people in the early stages of Alzheimer’s disease.
The company recruits seniors in churches, Walmart parking lots and other places to give them blood tests to see if they are at risk for the disease. Some people at the trial will receive Kisunla, while others will receive a placebo. Once enough participants were diagnosed with Alzheimer’s disease, Lilly would see and see if there was a difference between the person who received the drug and the person who received the placebo.
“If we can prevent it, even in half of the patients, it will be a revolution in how we view the diagnosis and treatment of Alzheimer’s disease,” Skovlensky said. “It may mark how to use it.” The main turning point for such drugs.”
A small vial of Alzheimer’s drug from Erieli Lilly is sold under the brand Kisunla.
Source: Eli Lilly
Eli Lilly has also invested heavily in gene therapy at a time when the field is facing significant uncertainty. Last summer, the company opened the $700 million Eli Lilly Institute for Genetic Medicine in Boston, away from the work of the Eli Lilly Indianapolis headquarters and one of the epicenters of the United States.
Biopharmaceutical companies of all sizes are working to turn the potential of scientific breakthroughs, such as the gene editing technology CRISPR-CAS9, into sensational drugs. One of them has been figuring out how to incorporate treatments into the body or the destination for delivery.
“The reality is that local delivery will be a small rule for human health, but once we cracked that, I think Lily is the company that could crack it because when we think about delivering it to other organizations, it’s not just Genetic Medicine, how do you package antibodies or small molecules?
Lilly uniquely occupied the big fluctuations. Whether they can be beaten remains to be seen.
